S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

SNDX Syndax Pharmaceuticals Inc

14.25

0.02 (0.14%)

Pre Market

Last Updated: 00:54:04

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Syndax Pharmaceuticals Charts.

Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Syndax Pharmaceuticals Charts.

Syndax Pharmaceuticals Inc News

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial
Monday 9 December 2024 (3 days ago) • PR Newswire (US)

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
Sunday 8 December 2024 (5 days ago) • PR Newswire (US)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Saturday 7 December 2024 (6 days ago) • Edgar (US Regulatory)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Wednesday 4 December 2024 (1 week ago) • PR Newswire (US)

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference
Wednesday 27 November 2024 (2 weeks ago) • PR Newswire (US)

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Saturday 16 November 2024 (4 weeks ago) • PR Newswire (US)

Form 8-K - Current report
Tuesday 12 November 2024 (1 month ago) • Edgar (US Regulatory)

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Tuesday 12 November 2024 (1 month ago) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 6 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 6 November 2024 (1 month ago) • Edgar (US Regulatory)

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
Wednesday 6 November 2024 (1 month ago) • PR Newswire (US)

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
Wednesday 6 November 2024 (1 month ago) • PR Newswire (US)

More Syndax Pharmaceuticals Inc News Articles

BNP Paribas Issuance

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions